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Abstract
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease, which is autoimmune in
origin and is characterized by the presence of autoantibodies directed against nuclear antigens. It
is a multi-system disease, and patients can present in vastly different ways. Prevalence varies with
ethnicity, but is estimated to be about 1 per 1000 overall with a female to male ratio of 10:1. The
clinical heterogeneity of this disease mirrors its complex aetiopathogenesis, which highlights the
importance of genetic factors and individual susceptibility to environmental factors. SLE can affect
every organ in the body. The most common manifestations include rash, arthritis and fatigue. At
the more severe end of the spectrum, SLE can cause nephritis, neurological problems, anaemia and
thrombocytopaenia. Over 90% of patients with SLE have positive anti-nuclear antibodies (ANA).
Significant titres are accepted to be of 1:80 or greater. SLE is a relapsing and remitting disease, and
treatment aims are threefold: managing acute periods of potentially life-threatening ill health,
minimizing the risk of flares during periods of relative stability, and controlling the less life-
threatening, but often incapacitating day to day symptoms. Hydroxychloroquine and non-steroidal
anti-inflammatory drugs are used for milder disease; corticosteroids and immunosuppressive
therapies are generally reserved for major organ involvement; anti-CD20 monoclonal antibody is
now used in patients with severe disease who has not responded to conventional treatments.
Despite enormous improvements in prognosis since the introduction of corticosteroids and
immunosuppressive drugs, SLE continues to have a significant impact on the mortality and
morbidity of those affected.
Disease name and synonyms
Systemic lupus erythematosus
Lupus
Definition/Diagnostic criteria
Systemic lupus erythematosus (SLE) is a clinically hetero-
geneous disease which is autoimmune in origin, and char-
acterized by the presence of autoantibodies directed
against nuclear antigens. It is, by definition, a multi-sys-
tem disease, and patients can present in vastly different
ways. Classification criteria have been developed, in part
in an attempt to keep the patient group as homogeneous
as possible for research purposes.
These criteria (Table 1), which are published by the Amer-
ican College of Rheumatology (ACR), were revised in
1982 [1] and combine clinical signs and symptoms with
abnormalities detected in blood tests such as a positive
anti-nuclear antibody or thrombocytopaenia. They were
further updated in 1997 [2] to reflect a greater under-
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standing of the role of antiphospholipid antibodies in
patients with SLE.
Epidemiology
SLE is up to 10 times more common in women than men,
and typically has a predilection for women in their child-
bearing years [3]. Reliable data about the prevalence of
SLE are difficult to come by. Variable methods for data
collection and inconsistency regarding case definition
contribute to this problem, but it is clear that the statistics
vary with ethnicity. The overall prevalence is estimated to
be about 1 per 1000. A study from Birmingham, UK,
found the prevalence to be 27.7/100,000 in the general
population, but nearly 9 times higher in Afro-Caribbean
females [4]. Data from a national health survey in the USA
found the self-reported prevalence of SLE (defined as hav-
ing been given a diagnosis of SLE by a physician) to be
241/100,000 [5]. Recognizing that this may well be an
over-estimate, combining self-reporting with evidence of
a current prescription for anti-malarials, corticosteroids,
or other immunosuppressive medications reduced this
figure to 53.6/100,000 [5].
Aetiology/Pathogenesis
The clinical heterogeneity of this disease is mirrored by its
complex aetiopathogenesis (reviewed in [6]). Twin stud-
ies initially indicated the importance of genetic factors,
and genome screening has highlighted a number of
potential loci of interest [7]. In the susceptible individual,
disease may result from a variety of environmental triggers
including exposure to sunlight, drugs and infections, par-
ticularly with Epstein-Barr virus. Even within one patient,
lupus flares can result from different precipitants at differ-
ent times.
Despite extensive work, the precise pathological mecha-
nisms of SLE are still not fully understood. The majority
of patients have elevated levels of autoantibodies, directed
in particular against nuclear components such as nucleo-
somes, DNA and histones, and it is generally accepted that
at least some of these have a directly pathogenic role,
either by precipitating as immune complexes in target
organs or by cross-reacting with other functionally rele-
vant antigens. The presence and persistence of these
autoantibodies indicate an abnormality in tolerance,
which results from a combination of abnormal handling
of autoantigens following apoptosis, and deranged func-
tion of T and B lymphocytes.
Differential diagnosis
The list of possible differential diagnoses is broad, and
will vary with the presentation of each case. The non-spe-
cific clinical features of widespread pain and fatigue mean
that in some cases fibromyalgia and other chronic pain
syndromes may be appropriate differentials. Indeed, it is
important to note that fibromyalgia and SLE can co-exist
in the same patient.
A number of patients will present with a cluster of features
suggestive of an autoimmune rheumatic disease, though
at initial presentation the final diagnosis appears unclear.
A proportion of these "undifferentiated" patients will go
on to develop full blown SLE, or other diseases such as
systemic sclerosis.
Some malignancies, particularly lymphoma and leukae-
mia, which are relevant to this age-group, can present with
a similar clinical picture. Similarly, there is significant
overlap with the presentation of some infections, notably,
Table 1: Diagnostic criteria of SLE. Adapted from Tan et al, 1982 [1]. A person is said to have SLE if he/she meets any 4 of these 11 
criteria simultaneously or in succession
Criterion Definition/examples
1. Malar rash Fixed erythema over the malar eminences, tending to spare the 
nasolabial folds
2. Discoid rash Erythematosus raised patches, may scar
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight
4. Oral ulcers Usually painless
5. Arthritis Non-erosive: Jaccoud's arthropathy
6. Serositis a) Pleuritis – pleuritic pain, pleural rub, pleural effusion b) Pericarditis – 
ECG changes, rub, pericardial effusion
7. Renal disorder a) Proteinuria (> 3+ or 0.5 g/day) b) Cellular casts in urine
8. Neurological disorder a) Seizures b) Psychosis
9. Haematological disorder a) Haemolytic anaemia b) Leukopaenia c) Lymphopaenia d) 
Thrombocytopaenia
10. Immunological disorder a) Anti-DNA antibodies b) Anti-Sm antibodies c) Anti-phospholipid 
antibodies
11. Anti-nuclear antibody Exclude drug causesOrphanet Journal of Rare Diseases 2006, 1:6 http://www.OJRD.com/content/1/1/6
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tuberculosis, HIV/AIDS and bacterial endocarditis. In
view of the immunosuppressive nature of the required
drugs, it is clearly crucial to exclude underlying infection
before starting treatment for SLE.
The acutely ill patient
Even when the diagnosis of SLE has been established, the
acutely ill patient must be thoroughly assessed before the
illness is presumed to be due to a flare of their lupus. Since
both SLE itself and the drugs used to treat it can cause
immunosuppression, sepsis is common and may present
in atypical ways. Thus, the physician must remain vigilant
in looking for infection. In addition, the possibility of cat-
astrophic antiphospholipid syndrome should be consid-
ered. We are becoming increasingly aware of this rare, but
devastating association. A recent paper [8] describes a
series of 80 such patients. The occlusion of multiple small
vessels results in multi-organ failure, and mortality was
reported to be 48% in this group.
Clinical manifestations
The clinical features of SLE are diverse and will be dis-
cussed by system as much as possible, and where appro-
priate, each section will refer to a review for more
information. Quoted frequencies of each disease manifes-
tation come from a prospective European study which fol-
lowed 1000 patients with SLE over 10 years [3].
Constitutional symptoms such as fatigue, weight loss and
fever are not life threatening, but have a significant impact
on quality of life. Patients with SLE describe overwhelm-
ing fatigue and unsatisfying sleep, though the extent to
which this tiredness relates directly to lupus disease activ-
ity remains controversial [9].
Renal disease affects about 30% of patients with SLE, and
remains the most dangerous, life-threatening complica-
tion. Patients who will develop lupus nephritis most com-
monly do so within the first few years of their disease. As
renal involvement is often asymptomatic, particularly ini-
tially, regular urinalysis and blood pressure monitoring is
crucial. Renal involvement is characterized by proteinuria
(> 0.5 g/24 hours), and/or red cell casts, and early referral
for renal biopsy is generally advocated. The histological
classification of lupus nephritis has recently been updated
[10]. Table 3 shows the revised classification criteria,
developed under the auspices of the International Society
of Nephrology and the Renal Pathology Society. Lupus
nephritis classes I-V describe mesangial (I, II), prolifera-
tive (III, IV) or membranous (V) lesions, and each biopsy
may have features of more than one class of disease.
Classes III and IV are subdivided further depending on the
activity or chronicity of the abnormalities seen. Class VI is
reserved for widespread sclerotic disease. The renal biopsy
findings are used to assess prognosis and guide manage-
ment. Response to treatment can be assessed using serial
urine protein/creatinine ratios, in addition to other more
general measures of disease activity (see below).
Neuropsychiatric lupus (NPSLE) is seen in about 20% of
cases. NPSLE is often a difficult diagnosis to make. Not
only are there 19 different clinical manifestations as
described by the American College of Rheumatology [11]
(Table 3), but there is also no single, simple diagnostic
test. In many cases, a brain biopsy would be the only
definitive test, and this is rarely performed. The clinical
features vary from central nervous system disease causing
headache and seizures, or psychiatric diagnoses including
Table 2: The revised classification of glomerulonephritis in SLE [10]
Class I Minimal mesangial lupus nephritis Normal on light microscopy. Mesangial immune deposits on immunofluorescence
Class II Mesangial proliferative lupus nephritis Mesangial hypercellularity or matrix expansion, with mesangial immune deposits on 
immunofluorescence
Class III Focal lupus nephritis Glomerulonephritis involving < 50% of glomeruli, typically with sub-endothelial immune deposits.
Class IV Diffuse lupus nephritis Glomerulonephritis involving > 50% of glomeruli, typically with sub-endothelial immune deposits. Can be 
segmental or global.
Class V Membranous lupus nephritis Global or segmental sub-epithelial immune deposits
Class VI Advanced sclerotic lupus nephritis > 90% of glomeruli globally sclerosed without residual activity
Table 3: Neuropsychiatric syndromes seen in systemic lupus 
erythematosus [11]
Central nervous system Peripheral nervous system
Aseptic meningitis Acute inflammatory polyneuropathy
Cerebrovascular disease Autonomic disorder
Demyelinating syndrome Mononeuropathy (single or multiplex)
Headache Myasthenia gravis
Movement disorder Cranial neuropathy
Myelopathy Plexopathy
Seizure disorders Polyneuropathy
Acute confusional state
Anxiety disorder
Cognitive dysfunction
Mood disorder
PsychosisOrphanet Journal of Rare Diseases 2006, 1:6 http://www.OJRD.com/content/1/1/6
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depression and psychosis, to peripheral nervous system
involvement causing neuropathy.
The investigations of choice will vary with the presenta-
tion. Central nervous system disease usually warrants
magnetic resonance imaging (MRI) of brain or spinal
cord, and examination of the cerebrospinal fluid where
appropriate. It must be remembered, however, that nor-
mal investigations, and lack of evidence of disease activity
in another system, do not rule out the diagnosis of NPSLE
– in a recent study of MRI in patients with NPSLE, 34%
had normal brain scans [12]. This included patients with
focal disease clinically. Interestingly, only one of the 85
patients included in this study proceeded to brain biopsy,
which is probably indicative of generally accepted prac-
tice.
The frequency of musculoskeletal disease in SLE means
that rheumatologists often make the initial diagnosis.
Arthralgia and myalgia occur in most patients. The classi-
cal "Jaccoud's arthropathy" although not causing a
destructive arthritis, can result in significant deformity
and functional impairment. A rheumatoid-like arthritis is
seen more rarely, sometimes associated with a positive
rheumatoid factor. Similarly, an overlap with myositis
also occurs.
Skin involvement in lupus is also very common. In addi-
tion to the classic malar and discoid rashes, more general-
ized photosensitivity is often present, and furthermore
sun exposure is known to trigger systemic disease flares.
Alopecia can be scarring when associated with discoid
lesions, or more diffuse, often fluctuating with disease
activity. Recurrent crops of mouth ulcers are also a feature
of active disease. Other oral manifestations include dry-
ness as a result of secondary Sjogren's syndrome, and
these patients also experience dryness of the eyes and
vagina.
Haematological features include normocytic normochro-
mic anaemia, thrombocytopaenia (sometimes, but not
always associated with antiphospholipid antibodies) and
leukopaenia. Severe haematological disease can occur, but
this is relatively rare [13].
Pleuritis , causing chest pain, cough and breathlessness, is
the most common pulmonary manifestation of SLE [14].
Although pleuritic symptoms may relate directly to active
lupus, pulmonary embolism must always be considered,
particularly in those who have antiphospholipid antibod-
ies. Pleural effusions are usually exudates, have low levels
of complement, and test positive for anti-nuclear antibod-
ies (ANA). Infections are common, and any parenchymal
lesion must be treated as infectious until proven other-
wise. Rarer complications include interstitial lung disease
and pulmonary hypertension (both more common in sys-
temic sclerosis) and pulmonary haemorrhage.
Gastrointestinal involvement [15] most commonly results
in non-specific abdominal pain and dyspepsia though it
can be unclear whether such pain results from the illness
itself or from drug side-effects. Hepatosplenomegaly can
come and go with disease activity. Mesenteric vasculitis is
very rare, but can be life-threatening, especially if it leads
to perforation, and may only be diagnosed at laparotomy.
SLE is associated with a variety of vascular manifestations.
Raynaud's phenomenon, causing the classical triphasic
colour change, was seen in 16% of patients in the Euro-
pean study[3]. Abnormalities in the micro vasculature are
also thought to account for the association with livedo
reticularis. Arterial and venous thrombosis affected up to
10% of the cohort, particularly in association with the sec-
ondary antiphospholipid syndrome.
In the last decade, it has become clear that patients with
SLE are at increased risk of atherosclerosis. Chronic inflam-
mation and the use of corticosteroids contribute to this
risk, and have led rheumatologists to treat SLE as an inde-
pendent risk factor for stroke and myocardial infarction,
much as an endocrinologist might regard the risk associ-
ated with diabetes. Ward [16] showed that in women
between 18 and 44 years of age, those with SLE were twice
as likely to develop a myocardial infarction or stroke, and
nearly 4 times as likely to present with heart failure.
Screening for cardiac disease with echocardiography
(ECHO) has established that asymptomatic valvular
lesions are common. In addition, pericarditis and pericar-
dial effusions are common though myocardial disease is
relatively rare.
Laboratory findings
Over 90% of patients with SLE have positive anti-nuclear
antibodies (ANA). Significant titres are accepted to be of
1:80 or greater. ANA although sensitive, is far from spe-
cific for SLE. A positive ANA is also seen in many other ill-
nesses including systemic sclerosis and polymyositis, as
well as some chronic infections. All patients should be
screened for extractable nuclear antigens (ENA). Different
ENAs are associated with different disease manifestations
– for instance, anti-Sm is associated with renal involve-
ment, and anti-Ro with secondary Sjogren's syndrome.
Antibodies to double-stranded DNA (dsDNA), and more
recently to nucleosomes (though this test is not com-
monly available in most routine labs) are more specific
for SLE, and anti-dsDNA titres are also predictive of renal
involvement. Moreover the titres of these antibodies fluc-
tuate with disease activity and therefore serial testing is aOrphanet Journal of Rare Diseases 2006, 1:6 http://www.OJRD.com/content/1/1/6
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useful monitoring tool. Typically, a disease flare is accom-
panied by a rising titre of dsDNA antibodies and erythro-
cyte sedimentation rate (ESR), and falling complement
and lymphocyte count. The C-reactive protein (CRP),
unlike the ESR, does not usually rise with disease activity
unless there is arthritis or serositis, and a raised CRP in a
patient with SLE must always make you consider infec-
tion.
Treatment
SLE is a relapsing and remitting disease, and treatment
aims are threefold: managing acute periods of potentially
life-threatening ill health, minimizing the risk of flares
during periods of relative stability, and controlling the less
life-threatening, but often incapacitating day to day symp-
toms. Our limited understanding of the precise pathogen-
esis of SLE means that the majority of treatments are still
broadly immunosuppressive in action, and hence carry a
significant risk of adverse effects.
At the milder end of the spectrum, hydroxychloroquine is
commonly used. This is effective for skin disease, joint
pain and fatigue. Non-steroidal anti-inflammatory drugs
are also useful for arthralgia and arthritis, though more
aggressive treatment with methotrexate may be required.
Low dose oral steroids or intramuscular injections of
depot steroid preparations are sometimes used for mild
disease, but immunosuppressive therapies and high dose
steroids are generally reserved for major organ involve-
ment.
Lupus nephritis remains the complication which carries
with it the biggest risk of death or long-term morbidity.
Treatment of renal disease (Cochrane review [17]) was
standardized by the National Institute of Health guide-
lines [18] published in 1992. Combining high dose corti-
costeroids with cyclophosphamide was the gold standard
in the management of proliferative lupus nephritis for
many years. Although efficacious, this regimen is limited
by significant toxicity. Both agents are immunosuppres-
sive. In addition, corticosteroids are associated with a
whole host of adverse effects including osteoporosis and
weight gain, and cyclophosphamide can cause haemor-
rhagic cystitis and infertility. More recently, the classic reg-
imen of monthly boluses of 1g cyclophosphamide for 6
months, followed by once every three months for the next
2 years, has been modified by some groups, who instead
advocate the use of "low-dose" cyclophosphamide (6 fort-
nightly pulses of 500 mg). The so-called Euro-lupus trial,
published in 2002, showed that the use of this lower dose
regimen has better outcomes in terms of infertility risk,
with no deleterious impact on renal disease [19]. Follow-
ing remission induction, azathioprine is commonly used
for maintenance therapy. Mycophenolate mofetil [20] has
been added to the repertoire of drugs used for the treat-
ment of lupus nephritis. This is now used commonly as
maintenance therapy following cyclophosphamide, and
its use in the induction phase has been adopted in some
centres.
Similarly, immunosuppressive treatments, such as cyclo-
phosphamide and azathioprine, are also used for central
nervous system involvement and rarely, serositis and hae-
matological disease. Furthermore, persistent autoimmune
thrombocytopenia sometimes requires immunoglobulin.
In an attempt to improve management, biological thera-
pies are being developed, which target specific cells or
molecules within the abnormally functioning immune
system. For example, the depletion of B cells using rituxi-
mab, an anti-CD20 monoclonal antibody previously used
in the treatment of B cell lymphomas, is now being used
in patients with severe disease which has not responded to
conventional treatments [21].
Prognosis
Despite significant advances in treatment over the last
decade, SLE still caries a significant risk of mortality and
long term morbidity. A European study of 1000 patients
with SLE, demonstrated a 10 year survival probability of
92% overall, reduced to 88% in those who presented with
nephropathy [3]. Mean age at death was 44, but varied
widely from 18–81 years.
Cause of death varies with disease duration. In one cohort
[22]), renal lupus accounted for the biggest number of
deaths in those with less than 5 years of disease, whereas
vascular disease was the most important factor in the
group who died later in the disease course.
As mentioned previously, we are becoming increasingly
aware of the impact that premature atherosclerosis is hav-
ing on the long term prognosis of lupus patients who sur-
vive the early years of illness. As we develop better
immune targeted therapies, optimizing the management
of these longer term complications will become increas-
ingly important.
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